Kynam Capital Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Kynam Capital Management’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-442,704	Closed	-$3.52M	–	24
2023 Q4	$3.52M	Sell	442,704 -287,768	-39%	-$1.93M	0.39%	24
2023 Q3	$4.73M	Buy	730,472 +1,395	+0.2%	+$9.54K	0.77%	22
2023 Q2	$4.51M	Hold	729,077	–	–	0.62%	19
2023 Q1	$2.81M	Sell	729,077 -4,849	-0.7%	-$17.7K	0.36%	25
2022 Q4	$2.28M	Buy	733,926 +2,405	+0.3%	+$8.91K	0.35%	26
2022 Q3	$2.94M	Sell	731,521 -26,327	-3%	-$120K	0.62%	26
2022 Q2	$3.69M	Buy	757,848 +88,748	+13%	+$568K	0.94%	20
2022 Q1	$6M	Buy	669,100 +430,059	+180%	+$3.92M	1.95%	16
2021 Q4	$2.69M	Buy	+239,041	New	+$3.22M	1.44%	20

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Kynam Capital Management's CNTA Position: Q1 2024 in Review

Kynam Capital Management sold out of Centessa Pharmaceuticals (CNTA) in Q1 2024, closing a stake of 442,704 shares — an estimated $3.52M sold.

Kynam Capital Management first reported a position in CNTA in Q4 2021 and held it in 9 quarters. The position peaked at $6M in Q1 2022. 69 funds tracked by Wall St. Rank hold CNTA as of Q1 2024.

Kynam Capital Management reported no remaining Centessa Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Kynam Capital Management sold 442,704 Centessa Pharmaceuticals shares in Q1 2024, an estimated $3.52M.
Kynam Capital Management first reported a position in Centessa Pharmaceuticals in Q4 2021 and held it in 9 quarters.
Kynam Capital Management's Centessa Pharmaceuticals position peaked at $6M in Q1 2022.
69 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2024.

Based on Kynam Capital Management's 13F filing for Q1 2024, filed 15 May 2024.